HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $20
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Spruce Biosciences (NASDAQ:SPRB) with a Buy and lowers the price target from $30 to $20.
Credit Suisse Maintains Outperform on Spruce Biosciences, Lowers Price Target to $6
Credit Suisse analyst Tiago Fauth maintains Spruce Biosciences (NASDAQ:SPRB) with a Outperform and lowers the price target from $26 to $6.
10 Biggest Price Target Changes For Tuesday
B of A Securities cut the price target on Oatly Group AB (NASDAQ: OTLY) from $32 to $11. Oatly Group shares fell 0.6% to $9.30 in pre-market trading.
SVB Leerink Downgrades Spruce Biosciences to Market Perform, Lowers Price Target to $5
SVB Leerink analyst Joseph Schwartz downgrades Spruce Biosciences (NASDAQ:SPRB) from Outperform to Market Perform and lowers the price target from $35 to $5.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 22)
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 20)